Optiflux® High Flux Dialyzers
Clinically Proven Albumin-sparing Design4
Keep Albumin Where It Belongs
Dialyzers help rid waste from your patient's bloodstream. But what if they're also losing something beneficial?
Optiflux® high flux dialyzers are designed to help patients limit albumin loss. In fact, in a retrospective data analysis, patients using the Optiflux dialyzer were observed to have significant increases (0.07 g/dL) in mean serum albumin after six months of treatments.1
For details, watch our short product video or download our Why Albumin Matters brochure.
Clinical Perspectives on Acceptable Albumin Loss per Treatment2
A recent perception survey shows that most nephrologists won't tolerate albumin loss during dialysis.
1g of Albumin Loss
72% of nephrologists find 1g of albumin loss level per treatment acceptable
2g of Albumin Loss
41% of nephrologists find 2g of albumin loss level per treatment acceptable
3g of Albumin Loss
27% of nephrologists find 3g of albumin loss level per treatment acceptable
In the recent perception survey, we asked physicians why they would probably or definitely switch from current high-flux dialyzers if albumin loss was 2g, 3g, or 4g. Here's what they said:
"Patient care impact and potential cost if replacement albumin is required."
"It is very hard for many patients to increase their protein intake to make up for this."
"Too much loss. Malnutrition is too big a problem."
"Hypoalbuminemia is one of the biggest patient risk factors and one of the hardest things to treat!"
Your Patients Rely on You. You Can Rely on Optiflux.
Reliable efficacy has made Optiflux dialyzers the time-tested choice of clinicians around the country, which is why we've achieved a landmark of 550 million+ treatments. And with the largest dialyzer manufacturing facility in the US, and a fleet of TruBlu delivery vehicles, customers can count on us to provide what they need, when they need it.
For more evidence of how we help you and your patients, see our proof points below.
Mean spKt/V of 1.9 ± 0.313,4 in a controlled study of 17 subjects.
Albumin loss below the detection limit of 0.3 g per treatment4 means patients retain nearly all of this vital protein.
No Evidence of Overt Complement Activation3
Quality You Can Quantify
Low customer complaint rates6 reflect reliable performance and engineering.
Supply You Can Count On
Manufactured locally in the US in a facility producing over 55 million dialyzers a year.6
Delivery You Can Depend On
Distribution centers in key locations, a fleet of long-haul trucks, and a 99% order fill rate.7
- Ficociello L, Li Y, Mullon C, Costanzo M, Kossmann RJ. 2019. Retrospective Analysis of Serum Albumin and Other Biomarkers in Chronic Hemodialysis Patients Dialyzed with the Optiflux F180NR Dialyzer. ASN 2019 abstract.
- An August 2019 Dialyzer Value Study, Ipsos survey of 108 nephrologists, Fresenius Medical Care North America, Renal Therapies Group, Waltham, MA, United States.
- Meyer, J, Steer, D, Weber, L, Zeitone, A, Thakuria, M, Hong-Ho, C, Vemula, S, Aslam, S, Mullon, C, Kossmann, R. 2019. Clinical Study to Assess the Performance of a Novel Dialyzer with Endexo® in End-Stage Renal Disease (ESRD) Subjects. ASN Abstract 09/2019.
- Dialysis adequacy is a function of many factors, including the rate of blood flow through the dialyzer, time on dialysis, and other factors.
- Krieter, D, Lemke, H, & Wanner, C 2008. A New Synthetic Dialyzer with Advanced Permselectivity for Enhanced Low-Molecular Weight Protein Removal. Artif. Organs 32, 547-554.
- Data on file, June 2019
- FMCNA results as of July 2019
Indications for use: Optiflux F160NRe, F180NRe, F200NRe and F250NRe dialyzers are intended for patients with acute or chronic renal failure when conservative therapy is judged to be inadequate. The suitability of a dialyzer for a particular treatment is the responsibility of the physician.
Caution: Federal (US) law restricts these devices to sale by or on order of a physician.
Note: Read the Instructions for Use for safe and proper use of these devices. For a complete description of hazards, contraindications, side effects and precautions, see full package labeling at www.fmcna.com. In rare cases, thrombocytopenia or hypersensitivity reactions including anaphylactic or anaphylactoid reactions to the dialyzer, or other elements in the extracorporeal circuit may occur during hemodialysis.
© 2020 Fresenius Medical Care. All Rights Reserved. Fresenius Medical Care, the triangle logo, Fresenius Polysulfone, and Optiflux are trademarks of Fresenius Medical Care Holdings, Inc. or its affiliated companies. All other trademarks are the property of their respective owners. P/N 104161-01 Rev B 07/2020